Literature DB >> 27741441

Chronic hepatitis C virus infection and pathogenesis of hepatocellular carcinoma.

Simonetta Bandiera1, C Billie Bian2, Yujin Hoshida2, Thomas F Baumert3, Mirjam B Zeisel4.   

Abstract

Hepatitis C virus (HCV) infection is one of the major causes of advanced liver disease and hepatocellular carcinoma (HCC) worldwide. While the knowledge about the molecular virology of HCV infection has markedly advanced, the molecular mechanisms of disease progression leading to fibrosis, cirrhosis and HCC are still unclear. Accumulating experimental and clinical studies indicate that HCV may drive hepatocarcinogenesis directly via its proteins or transcripts, and/or indirectly through induction of chronic liver inflammation. Despite the possibility to eradicate HCV infection through direct-acting antiviral treatment, the risk of HCC persists although specific biomarkers to estimate this risk are still missing. Thus, a better understanding of HCV-induced HCC and more physiological liver disease models are required to prevent cancer development.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 27741441      PMCID: PMC5120759          DOI: 10.1016/j.coviro.2016.09.010

Source DB:  PubMed          Journal:  Curr Opin Virol        ISSN: 1879-6257            Impact factor:   7.121


  72 in total

1.  Gas6/Axl pathway is activated in chronic liver disease and its targeting reduces fibrosis via hepatic stellate cell inactivation.

Authors:  Cristina Bárcena; Milica Stefanovic; Anna Tutusaus; Leonel Joannas; Anghara Menéndez; Carmen García-Ruiz; Pau Sancho-Bru; Montserrat Marí; Joan Caballeria; Carla V Rothlin; José C Fernández-Checa; Pablo García de Frutos; Albert Morales
Journal:  J Hepatol       Date:  2015-04-20       Impact factor: 25.083

2.  HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons.

Authors:  Emmanuel Thomas; Veronica D Gonzalez; Qisheng Li; Ankit A Modi; Weiping Chen; Mazen Noureddin; Yaron Rotman; T Jake Liang
Journal:  Gastroenterology       Date:  2012-01-13       Impact factor: 22.682

Review 3.  Impact of hepatitis C virus eradication on hepatocellular carcinogenesis.

Authors:  Darrick K Li; Raymond T Chung
Journal:  Cancer       Date:  2015-06-16       Impact factor: 6.860

Review 4.  Innate and adaptive immune responses in HCV infections.

Authors:  Markus H Heim; Robert Thimme
Journal:  J Hepatol       Date:  2014-11-03       Impact factor: 25.083

5.  Hepatitis C virus core protein epigenetically silences SFRP1 and enhances HCC aggressiveness by inducing epithelial-mesenchymal transition.

Authors:  H Quan; F Zhou; D Nie; Q Chen; X Cai; X Shan; Z Zhou; K Chen; A Huang; S Li; N Tang
Journal:  Oncogene       Date:  2013-06-17       Impact factor: 9.867

6.  HCV core-mediated activation of latent TGF-β via thrombospondin drives the crosstalk between hepatocytes and stromal environment.

Authors:  Nassima Benzoubir; Charlène Lejamtel; Serena Battaglia; Barbara Testoni; Barbara Benassi; Claire Gondeau; Laure Perrin-Cocon; Christophe Desterke; Valérie Thiers; Didier Samuel; Massimo Levrero; Christian Bréchot; Marie-Françoise Bourgeade
Journal:  J Hepatol       Date:  2013-08-06       Impact factor: 25.083

7.  A lymphotoxin-driven pathway to hepatocellular carcinoma.

Authors:  Johannes Haybaeck; Nicolas Zeller; Monika Julia Wolf; Achim Weber; Ulrich Wagner; Michael Odo Kurrer; Juliane Bremer; Giandomenica Iezzi; Rolf Graf; Pierre-Alain Clavien; Robert Thimme; Hubert Blum; Sergei A Nedospasov; Kurt Zatloukal; Muhammad Ramzan; Sandra Ciesek; Thomas Pietschmann; Patrice N Marche; Michael Karin; Manfred Kopf; Jeffrey L Browning; Adriano Aguzzi; Mathias Heikenwalder
Journal:  Cancer Cell       Date:  2009-10-06       Impact factor: 31.743

8.  Characteristics and prognosis of hepatocellular carcinoma detected in patients with chronic hepatitis C after the eradication of hepatitis C virus: A multicenter study from Japan.

Authors:  Hidenori Toyoda; Toshifumi Tada; Kunihiko Tsuji; Atsushi Hiraoka; Yoshihiko Tachi; Ei Itobayashi; Koichi Takaguchi; Tomonori Senoh; Daichi Takizawa; Toru Ishikawa; Takashi Kumada
Journal:  Hepatol Res       Date:  2015-11-19       Impact factor: 4.288

9.  Osteopontin and latent-TGF β binding-protein 2 as potential diagnostic markers for HBV-related hepatocellular carcinoma.

Authors:  Andre Nogueira da Costa; Amelie Plymoth; Daniela Santos-Silva; Sandra Ortiz-Cuaran; Suzy Camey; Paule Guilloreau; Suleeporn Sangrajrang; Thiravud Khuhaprema; Maimuna Mendy; Olufunmilayo A Lesi; Hee-Kyung Chang; Jin-Kyoung Oh; Duk-Hee Lee; Hai-Rim Shin; Gregory D Kirk; Philippe Merle; Laura Beretta; Pierre Hainaut
Journal:  Int J Cancer       Date:  2014-05-15       Impact factor: 7.396

10.  Signalling via the osteopontin and high mobility group box-1 axis drives the fibrogenic response to liver injury.

Authors:  Elena Arriazu; Xiaodong Ge; Tung-Ming Leung; Fernando Magdaleno; Aritz Lopategi; Yongke Lu; Naoto Kitamura; Raquel Urtasun; Neil Theise; Daniel J Antoine; Natalia Nieto
Journal:  Gut       Date:  2016-01-27       Impact factor: 23.059

View more
  26 in total

1.  Hepatitis C Virus core+1/ARF Protein Modulates the Cyclin D1/pRb Pathway and Promotes Carcinogenesis.

Authors:  Savvina Moustafa; Ioannis Karakasiliotis; Penelope Mavromara
Journal:  J Virol       Date:  2018-04-13       Impact factor: 5.103

2.  Viral persistence, liver disease, and host response in a hepatitis C-like virus rat model.

Authors:  Sheetal Trivedi; Satyapramod Murthy; Himanshu Sharma; Alex S Hartlage; Arvind Kumar; Sashi V Gadi; Peter Simmonds; Lokendra V Chauhan; Troels K H Scheel; Eva Billerbeck; Peter D Burbelo; Charles M Rice; W Ian Lipkin; Kurt Vandegrift; John M Cullen; Amit Kapoor
Journal:  Hepatology       Date:  2018-05-21       Impact factor: 17.425

3.  Purinoceptor expression in hepatocellular virus (HCV)-induced and non-HCV hepatocellular carcinoma: an insight into the proviral role of the P2X4 receptor.

Authors:  Madiha Khalid; Sobia Manzoor; Hassam Ahmad; Arun Asif; Tariq Ali Bangash; Amer Latif; Shahla Jaleel
Journal:  Mol Biol Rep       Date:  2018-10-20       Impact factor: 2.316

Review 4.  Molecular basis of hepatocellular carcinoma induced by hepatitis C virus infection.

Authors:  Mohammad Irshad; Priyanka Gupta; Khushboo Irshad
Journal:  World J Hepatol       Date:  2017-12-28

5.  Study on the value of serum miR-106b for the early diagnosis of hepatocellular carcinoma.

Authors:  Bao-Min Shi; Wen Lu; Kun Ji; Yu-Feng Wang; Shuai Xiao; Xiu-Yan Wang
Journal:  World J Gastroenterol       Date:  2017-05-28       Impact factor: 5.742

6.  Daclatasvir plus asunaprevir in treatment-naïve patients with hepatitis C virus genotype 1b infection.

Authors:  Lai Wei; Fu-Sheng Wang; Ming-Xiang Zhang; Ji-Dong Jia; Alexey A Yakovlev; Wen Xie; Eduard Burnevich; Jun-Qi Niu; Yong Jin Jung; Xiang-Jun Jiang; Min Xu; Xin-Yue Chen; Qing Xie; Jun Li; Jin-Lin Hou; Hong Tang; Xiao-Guang Dou; Yash Gandhi; Wen-Hua Hu; Fiona McPhee; Stephanie Noviello; Michelle Treitel; Ling Mo; Jun Deng
Journal:  World J Gastroenterol       Date:  2018-03-28       Impact factor: 5.742

7.  Epidemiology of Chronic Hepatitis C Infections at a Tertiary Care Centre in Oman.

Authors:  Said A Al-Busafi; Halima Al-Shuaili; Heba Omar; Haifa Al-Zuhaibi; L Jeyaseelan; Khalid Al-Naamani
Journal:  Sultan Qaboos Univ Med J       Date:  2018-01-10

8.  The Pannexin 1/Purinergic Receptor P2X4 Pathway Controls the Secretion of MicroRNA-Containing Exosomes by HCV-Infected Hepatocytes.

Authors:  Ok-Kyung Kim; Da-Eun Nam; Young S Hahn
Journal:  Hepatology       Date:  2021-08-30       Impact factor: 17.425

Review 9.  Viruses and Bacteria Associated with Cancer: An Overview.

Authors:  Davide Zella; Robert C Gallo
Journal:  Viruses       Date:  2021-05-31       Impact factor: 5.048

Review 10.  Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine.

Authors:  Naoto Fujiwara; Scott L Friedman; Nicolas Goossens; Yujin Hoshida
Journal:  J Hepatol       Date:  2017-10-06       Impact factor: 30.083

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.